Does neoadjuvant FOLFOX chemotherapy improve the oncological prognosis of high-risk stage II and III colon cancers ? Three years follow-up results of the Prodige 22 phase II randomized multicenter trial
ANNÉE
2020
AUTEURS
Karoui M, Gallois C, Piessen G, Legoux JL, Barbier E, De Chaisemartin C, Lecaille C, Bouche O, Ammarguellat H, Brunetti F, Prudhomme M, Regimbeau JM, Glehen O, Lievre A, Portier G, Hartwig J, Goujon G, Romain B, Lepage C, Taieb J, for PRODIGE 22 investigators/Collaborators
CONGRÈS/REVUE
ASCO
ÉTUDE
Localisation
LIEN PUBLICATIONS ASSOCIÉES